{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:13:35Z","timestamp":1755800015876},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.clim.2011.02.002","type":"journal-article","created":{"date-parts":[[2011,2,5]],"date-time":"2011-02-05T09:33:30Z","timestamp":1296898410000},"page":"105-106","source":"Crossref","is-referenced-by-count":3,"title":["Another new mechanism of action of IGIV"],"prefix":"10.1016","volume":"139","author":[{"given":"Melvin","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2011.02.002_bb0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2011.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(83)91109-1","article-title":"High dose intravenous gammaglobulin for Kawasaki disease","volume":"2","author":"Furusho","year":"1983","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1016\/j.clim.2011.02.002_bb0015","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl 3","key":"10.1016\/j.clim.2011.02.002_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2011.02.002_bb0025","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorder","author":"Ballow","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"year":"1971","series-title":"MRC Working Party on Hypogammaglobulinemia: Hypogammaglobulinemia in the United Kingdom","key":"10.1016\/j.clim.2011.02.002_bb0030"},{"key":"10.1016\/j.clim.2011.02.002_bb0035","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years","volume":"125","author":"Lucas","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/CCLM.1999.039","article-title":"CD14++ monocytes, CD14+\/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy","volume":"37","author":"Scherberich","year":"1999","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clim.2011.02.002_bb0045","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","article-title":"The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF","volume":"168","author":"Belge","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2011.01.002","article-title":"Preparations of intravenous immunoglobulin diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients","volume":"139","author":"Siedlar","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/1074-7613(95)90134-5","article-title":"The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fcgamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation","volume":"3","author":"Da\u00ebron","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2011.02.002_bb0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2567.2007.02588.x","article-title":"Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization","volume":"121","author":"Veri","year":"2007","journal-title":"Immunology"},{"issue":"Suppl 1","key":"10.1016\/j.clim.2011.02.002_bb0070","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s10875-010-9405-6","article-title":"A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs","volume":"3","author":"Anthony","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMcibr0803649","article-title":"The antiinflammatory IgG","volume":"359","author":"Kaveri","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2011.02.002_bb0080","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.clim.2011.02.002_bb0085","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1365-2249.2000.01321.x","article-title":"CD14+CD16+monocyte subpopulation in Kawasaki disease","volume":"121","author":"Katayama","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2011.02.002_bb0090","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1521-4141(200106)31:6<1716::AID-IMMU1716>3.0.CO;2-X","article-title":"CD14-dim\/CD16-bright monocytes in hemophagocytic lymphoid histiocytosis","volume":"31","author":"Emminger","year":"2001","journal-title":"Eur. J. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661611000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T01:28:26Z","timestamp":1543973306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661611000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1521661611000374"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2011.02.002","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}